Pediatric Myocardial Metabolism During Puberty: Mechanisms, Clinical Implications, and Emerging Insights

Abstract

Pediatric myocardial metabolism undergoes significant transformation during puberty, influenced by physiological hormonal surges and developmental changes. This review explores the epidemiology, underlying mechanisms, risk factors, clinical manifestations, diagnostic modalities, management strategies, and recent advances in understanding myocardial metabolism in pubertal children. The discussion synthesizes evidence from recent research, highlights clinical relevance, evaluates guideline recommendations, and identifies future directions for optimizing cardiovascular health in pediatric populations during this critical developmental window.

Introduction

Puberty represents a period of dynamic physiological and hormonal transitions that profoundly affect multiple organ systems, including the myocardium. Myocardial metabolism, pivotal for cardiac growth and function, is particularly sensitive to changes in substrate utilization, hormonal milieu, and metabolic demands during adolescence. Understanding the nuances of pediatric myocardial metabolism during puberty is essential for pediatricians, cardiologists, and researchers aiming to identify early risk factors for cardiometabolic disease, optimize patient outcomes, and guide preventive strategies.

Epidemiology / Disease Burden

While overt cardiovascular disease remains rare in pediatric populations, epidemiological data reveal increasing prevalence of metabolic syndrome, insulin resistance, and obesity among adolescents. These conditions are closely associated with subclinical myocardial metabolic dysfunction, which may presage future cardiovascular morbidity. Longitudinal cohort studies, such as the Bogalusa Heart Study and the National Health and Nutrition Examination Survey (NHANES), have documented a rising incidence of risk factors including dyslipidemia and hypertension during puberty, underscoring the importance of early metabolic assessment in this age group.

Pathophysiology

During puberty, myocardial energy substrate preference undergoes a shift from predominant fatty acid oxidation in childhood to increased reliance on glucose oxidation and glycolysis. This transition is mediated by heightened levels of growth hormone, sex steroids (estrogen, testosterone), and insulin-like growth factor-1 (IGF-1), which modulate key metabolic enzymes and transporter proteins. Enhanced sympathetic activity and tissue-specific insulin sensitivity changes further alter myocardial substrate uptake and utilization. Disruptions in these pathways, due to genetic predisposition or environmental factors, can impair myocardial energy efficiency and contribute to early cardiac remodeling.

Risk Factors

Several risk factors predispose pediatric patients to aberrant myocardial metabolism during puberty. These include obesity, sedentary lifestyle, family history of type 2 diabetes or premature cardiovascular disease, and exposure to endocrine-disrupting chemicals. Pubertal timing itself, with early or delayed onset, may influence cardiometabolic risk profiles. Additionally, pre-existing conditions such as congenital heart disease or chronic systemic illnesses can accentuate metabolic vulnerability during this period.

Clinical Features

Clinical manifestations of disrupted myocardial metabolism in pubertal children are often subtle and may include exercise intolerance, fatigue, or mild dyspnea. In more pronounced cases, clinical features may overlap with metabolic syndrome, including central adiposity, acanthosis nigricans, and hypertension. Echocardiographic findings may reveal early diastolic dysfunction or altered myocardial strain parameters, even in asymptomatic individuals. Recognition of these features requires a high index of clinical suspicion.

Diagnosis

Accurate assessment of myocardial metabolism during puberty necessitates a multimodal approach. Non-invasive imaging modalities, such as echocardiography with strain analysis and cardiac magnetic resonance imaging (MRI) with spectroscopy, enable evaluation of myocardial structure, function, and substrate utilization. Biochemical markers including fasting glucose, insulin, lipid profiles, and serum free fatty acids offer insight into systemic metabolic status. Advanced techniques, such as positron emission tomography (PET) with labeled substrates, provide precise quantification of myocardial glucose and fatty acid uptake, though their use is largely limited to research settings.

Treatment & Management

Management of altered myocardial metabolism in pubertal children centers on lifestyle modification, including optimization of physical activity, dietary patterns, and weight control. Early intervention in children with obesity or insulin resistance is crucial to mitigate progression to overt cardiometabolic disease. Pharmacological therapies, such as metformin, may be considered in select high-risk populations but require careful risk-benefit assessment. Ongoing collaboration between pediatricians, endocrinologists, and cardiologists is essential in formulating individualized care plans.

Recent Advances / Emerging Therapies

Recent research has elucidated novel molecular regulators of myocardial metabolism, including peroxisome proliferator-activated receptors (PPARs), AMP-activated protein kinase (AMPK), and mitochondrial biogenesis factors. Interventions targeting these pathways such as GLP-1 receptor agonists are under investigation for their potential to enhance myocardial metabolic flexibility and protect against cardiometabolic sequelae. Furthermore, digital health technologies, including wearable metabolic sensors, are emerging as tools for real-time monitoring and early detection of metabolic derangements in adolescents.

Guideline Recommendations

Current clinical guidelines emphasize early identification of at-risk youth through regular screening of anthropometric and metabolic parameters during puberty. The American Academy of Pediatrics and the Endocrine Society recommend annual assessment of body mass index (BMI), blood pressure, and fasting lipid/glucose profiles in adolescents with risk factors. Multidisciplinary management, incorporating nutritional counseling and exercise prescriptions, is advocated for optimizing metabolic and cardiovascular health in this population. Guideline-directed pharmacotherapy should be reserved for cases refractory to lifestyle interventions or with established metabolic disease.

Conclusion

Pediatric myocardial metabolism during puberty is governed by complex hormonal and metabolic interactions that have significant implications for lifelong cardiovascular health. Early recognition of risk factors, combined with targeted diagnostic and therapeutic strategies, can mitigate the potential progression to adult-onset cardiometabolic disease. Ongoing research and technological innovation promise to refine risk stratification and expand the therapeutic armamentarium for optimizing cardiac metabolism during this pivotal developmental period. Clinicians must remain vigilant in monitoring and supporting at-risk adolescents, guided by evolving evidence and expert consensus.